Prescribers’ Clinical Support System for Opioid Therapies (PCSS-O) is a three year grant funded by Substance Abuse and Mental Health Services Administration (SAMHSA),Center for Substance Abuse Treatment (CSAT). It is a collaborative project led by American Academy of Addiction Psychiatry (AAAP) with: American Dental Association (ADA), American Medical Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), American Psychiatric Association (APA), American Society for Pain Management Nursing (ASPMN), and International Nurses Society on Addictions (IntNSA). These organizations are providing training and education on the safe and effective prescribing of opioid medications in the treatment of pain and/or opioid addiction.
A webinar offered by American Osteopathic Academy of Addiction Medicine (AOAAM).
About the Webinar:
SCOPE of Pain is a three-part educational program that will help you safely and competently manage your patients with chronic pain. Through the case of Mary Williams, a 42 year old with painful diabetic neuropathy and chronic low back pain, you'll learn how to: 1) decide on appropriateness of opioid analgesics; 2) assess for opioid misuse risk; 3) counsel patients about opioid safety, risks and benefits; 4) competently monitor patients prescribed opioids for benefit and harm; 5) make decisions on continuing or discontinuing opioid analgesics; 6) safely discontinue opioids when there is too little benefit or too much risk and harm.
Date: September 25, 2013
Speaker: Daniel P. Alford, MD, MPH, FACP, FASAM
Time: 12:00 pm – 1:00 pm ET
To Register: https://events.r20.constantcontact.com/register/eventReg?oeidk=a07e81fet05adb049cd&oseq=&c=&ch=
Funding for this initiative was made possible (in part) by Prescribers’ Clinical Support System for Opioid Therapies (1H79TI023439) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reﬂect the ofﬁcial policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.